Showing results (1571-1580 of 1,642) with videos related to

Sort By:
Pageof 165
Alimentary Pharmacology & Therapeutics|May 6, 2022
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levelsSamuel A L Hall, Gareth S Burns, Despina Anagnostou, et al.
ACS Infectious Diseases|December 11, 2025
Bacterial Carbonic Anhydrase Inhibitor CAI0019 Demonstrates Efficacy in Enterococcus faecium Septicemic Peritonitis Mouse Model While Sparing the MicrobiomeNader S Abutaleb, Katrina J Holly, Carolyn K Metcalfe, et al.
Science Advances|June 4, 2025
Fecal metabolite profiling identifies critically ill patients with increased 30-day mortalityAlexander P de Porto, Nicholas P Dylla, Matthew Stutz, et al.
Molecular and Biochemical Parasitology|November 28, 2006
Genome-scale protein expression and structural biology of Plasmodium falciparum and related Apicomplexan organismsMasoud Vedadi, Jocelyne Lew, Jennifer Artz, et al.
The Journal of Infectious Diseases|September 15, 2022
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling PathwaysSamuel A L Hall, Gareth S Burns, Benjamin J Mooney, et al.
BMJ Open Diabetes Research & Care|January 11, 2025
Six months of hybrid closed-loop therapy improves diabetes-specific positive well-being, and reduces diabetes distress and fear of hypoglycemia: secondary analysis of a randomized controlled trialJennifer A Halliday, Sienna Russell-Green, Benjamin Lam, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 15, 2024
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapySimon J Hume, Danny K Wong, Man-Fung Yuen, et al.
Nature Communications|November 4, 2022
Immunomodulatory fecal metabolites are associated with mortality in COVID-19 patients with respiratory failureMatthew R Stutz, Nicholas P Dylla, Steven D Pearson, et al.
Diabetes Technology & Therapeutics|February 14, 2022
Driving with Type 1 Diabetes: Real-World Evidence to Support Starting Glucose Level and Frequency of Monitoring During JourneysSteven Trawley, Amanda N Stephens, Sybil A McAuley, et al.
Hepatology Communications|July 17, 2023
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participantsAlexander J Thompson, Kathy Jackson, Sara Bonanzinga, et al.
Pageof 165